{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:35:40Z","timestamp":1790832940624,"version":"4.1.0"},"reference-count":130,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"INNODOC-MED","award":["351058"],"award-info":[{"award-number":["351058"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Hepatoblastoma, the most common pediatric primary liver cancer, is no longer regarded as a conventional malignancy but rather as a tumor emerging from disrupted hepatic developmental processes. Although improvements in chemotherapy, surgical techniques, and liver transplantation have markedly enhanced survival, therapeutic decision-making is still primarily guided by anatomical criteria and insufficiently reflects the biological heterogeneity that contributes to variable treatment response and disease recurrence. This narrative review integrates recent advances in molecular biology, tumor stemness, microenvironmental interactions, and translational research models in pediatric hepatoblastoma. We critically examine how developmental signaling pathways, cellular plasticity, and immune\u2013vascular context shape tumor behavior and therapeutic vulnerability, with a focus on emerging targeted, anti-angiogenic, immune, and epigenetic strategies. Results: Hepatoblastoma is characterized by aberrant activation of key developmental pathways, including Wnt\/\u03b2-catenin, Hippo\u2013YAP, IGF, and mTOR signaling, which cooperate to sustain proliferation, stem-like phenotypes, and treatment resistance. Tumor heterogeneity is further reinforced by cancer stem cell populations and a predominantly immune-cold microenvironment. While innovative therapeutic approaches show promise, their clinical impact has been limited by biological complexity and insufficient integration into current treatment algorithms. Liquid biopsy biomarkers, advanced translational models, and multi-omics approaches offer new opportunities for biologically informed risk stratification and therapy adaptation. Conclusions: Future progress in pediatric hepatoblastoma will require a paradigm shift from purely clinicopathological management toward an integrated molecular and surgical framework. Incorporating biological stratification into therapeutic decision-making may enable personalized treatment, rational therapy de-escalation, and improved outcomes for high-risk disease. This review highlights the foundations and future directions for precision medicine in hepatoblastoma.<\/jats:p>","DOI":"10.3390\/cancers18050879","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:49:42Z","timestamp":1773071382000},"page":"879","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies"],"prefix":"10.3390","volume":"18","author":[{"given":"Ana Maria","family":"Scurtu","sequence":"first","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3018-8011","authenticated-orcid":false,"given":"Elena","family":"\u021aarc\u0103","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-7610","authenticated-orcid":false,"given":"Laura Mihaela","family":"Trandafir","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Belu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Jehac","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Martu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin","family":"Bernic","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7634-4297","authenticated-orcid":false,"given":"Rodica Elena","family":"Heredea","sequence":"additional","affiliation":[{"name":"Department of Clinical Practical Skills, Victor Babe\u015f University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viorel","family":"\u021aarc\u0103","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Apollonia University, 700511 Ia\u0219i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitrel","family":"B\u0103iceanu","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7859-840X","authenticated-orcid":false,"given":"Elena","family":"Cojocaru","sequence":"additional","affiliation":[{"name":"Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1038\/s41467-021-25430-9","article-title":"Genetic and epigenetic basis of hepatoblastoma diversity","volume":"12","author":"Nagae","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Fan, L., Na, J., Shi, T., and Liao, Y. (2025). Hepatoblastoma: From molecular mechanisms to therapeutic strategies. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32030149"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shi, K., Xu, C., Zhang, X., Liang, H., Li, X., Liu, B., and Wang, Q. (2025). Global trends and regional differences of hepatoblastoma: A systematic analysis and predictions to 2035 based on the global burden of disease study 2021. BMC Public Health, 25.","DOI":"10.1186\/s12889-025-24407-3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.17998\/jlc.2022.02.24","article-title":"Recent updates on the classification of hepatoblastoma according to the International Pediatric Liver Tumors Consensus","volume":"22","author":"Jeong","year":"2022","journal-title":"J. Liver Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102446","DOI":"10.1016\/j.eclinm.2024.102446","article-title":"The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: A scoping review of the problem and a proposed solution","volume":"69","author":"Geller","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-025-00620-7","article-title":"Hepatoblastoma","volume":"11","author":"Pio","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"BSR20192466","DOI":"10.1042\/BSR20192466","article-title":"Wnt\/\u03b2-catenin signaling as a useful therapeutic target in hepatoblastoma","volume":"39","author":"Sha","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.jbior.2023.100997","article-title":"Biology of childhood hepatoblastoma and the search for novel treatments","volume":"91","author":"Pihlajoki","year":"2023","journal-title":"Adv. Biol. Regul."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Fu, Y., Franc\u00e9s, R., Monge, C., Desterke, C., Marchio, A., Pineau, P., Chang-Marchand, Y., and Mata-Garrido, J. (2024). Metabolic and epigenetic mechanisms in hepatoblastoma: Insights into tumor biology and therapeutic targets. Genes, 15.","DOI":"10.3390\/genes15111358"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, H.S., Lao, J., Jiang, R.S., Wang, B., Ma, X.P., and Wang, J.Y. (2024). Summary of biological research on hepatoblastoma: A scoping review. Front. Pediatr., 12.","DOI":"10.3389\/fped.2024.1309693"},{"key":"ref_11","unstructured":"Musick, S.R., Smith, M., Rouster, A.S., and Babiker, H.M. (2026, January 25). Hepatoblastoma, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534795\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e71163","DOI":"10.1002\/cam4.71163","article-title":"Global burden of hepatoblastoma from 1990 to 2021 and projection to 2030","volume":"14","author":"Huang","year":"2025","journal-title":"Cancer Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e29763","DOI":"10.1002\/pbc.29763","article-title":"Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States","volume":"69","author":"Kahla","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jia, M., He, E., Sun, W., Cui, H., Zhao, H., Zhao, W., Liu, W., Guo, Z., Wang, Y., and Feng, W. (2025). Hepatoblastoma regional trends: Dynamic SDI and joinpoint regression analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14566-2"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/ajmg.a.62767","article-title":"Hepatoblastoma in molecularly defined, congenital diseases","volume":"188","author":"Nussbaumer","year":"2022","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Klein, S.D., DeMarchis, M., Linn, R.L., MacFarland, S.P., and Kalish, J.M. (2023). Occurrence of hepatoblastomas in patients with Beckwith\u2013Wiedemann Spectrum (BWSp). Cancers, 15.","DOI":"10.3390\/cancers15092548"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.5582\/bst.2023.01311","article-title":"An update on diagnosis and treatment of hepatoblastoma","volume":"17","author":"Cao","year":"2024","journal-title":"Biosci. Trends"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107700","DOI":"10.4251\/wjgo.v17.i6.107700","article-title":"Progress in the study of therapeutic strategies for hepatoblastoma in children","volume":"17","author":"Tang","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: A unified analysis from the Children\u2019s Hepatic Tumors International Collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2148013","DOI":"10.1001\/jamanetworkopen.2021.48013","article-title":"Independent assessment of the Children\u2019s Hepatic Tumors International Collaboration risk stratification for hepatoblastoma and the association of tumor histological characteristics with prognosis","volume":"5","author":"Zhou","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"21270","DOI":"10.1002\/cam4.6705","article-title":"Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy","volume":"12","author":"Espinoza","year":"2023","journal-title":"Cancer Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jpeds.2019.05.051","article-title":"Development of the serum \u03b1-fetoprotein reference range in patients with Beckwith-Wiedemann spectrum","volume":"212","author":"Duffy","year":"2019","journal-title":"J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MOP.0000000000000046","article-title":"Hepatoblastoma state of the art: Pathology, genetics, risk stratification, and chemotherapy","volume":"26","author":"Czauderna","year":"2014","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Trobaugh-Lotrario, A.D., Maibach, R., Aronson, D.C., Rangaswami, A., H\u00e4berle, B., O\u2019Neill, A.F., Schmid, I., Ansari, M., Hishiki, T., and Ranganathan, S. (2023). Outcomes of patients treated for hepatoblastoma with low alpha-fetoprotein and\/or small cell undifferentiated histology: A report from the Children\u2019s Hepatic Tumors International Collaboration (CHIC). Cancers, 15.","DOI":"10.3390\/cancers15020467"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhi, T., Zhang, W.L., Zhang, Y., Hu, H.M., Wang, Y.Z., and Huang, D.S. (2021). A new risk-stratification system for hepatoblastoma in children under six years old and the significance for prognosis evaluation: A 14-year retrospective study from a single center. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08095-x"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s00431-025-06498-7","article-title":"Prognostic factors and treatment outcomes of hepatoblastoma in children: A SEER database analysis","volume":"184","author":"Li","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s13304-025-02140-1","article-title":"Development and risk stratification of a prognostic nomogram for hepatoblastoma: Analysis of the SEER database","volume":"77","author":"He","year":"2025","journal-title":"Updates Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/his.15536","article-title":"Pathology reporting of hepatoblastoma resections: Recommendations from the international collaboration on cancer reporting","volume":"87","author":"Webster","year":"2025","journal-title":"Histopathology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/PAP.0000000000000495","article-title":"Hepatoblastoma: Comprehensive review with recent updates","volume":"32","author":"Jiao","year":"2025","journal-title":"Adv. Anat. Pathol."},{"key":"ref_30","unstructured":"WHO Classification of Tumours Editorial Board (2023). Paediatric Tumours. WHO Classification of Tumours, IARC Publications. [5th ed.]."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Selvaggi, F., Catalano, T., Cotellese, R., and Aceto, G.M. (2022). Targeting Wnt\/\u03b2-catenin pathways in primary liver tumours: From microenvironment signaling to therapeutic agents. Cancers, 14.","DOI":"10.3390\/cancers14081912"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00383-025-06116-5","article-title":"Novel CTNNB1 gene mutations reveal critical pathogenic mechanisms in pediatric hepatoblastoma","volume":"41","author":"Kumar","year":"2025","journal-title":"Pediatr. Surg. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8576","DOI":"10.1038\/s41467-024-52757-w","article-title":"Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids","volume":"15","author":"Kluiver","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Adams, J.M., and Jafar-Nejad, H. (2019). The roles of Notch signaling in liver development and disease. Biomolecules, 9.","DOI":"10.3390\/biom9100608"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2025.05.005","article-title":"Immune exclusion in hepatoblastoma: Is \u03b2-catenin to blame again?","volume":"83","author":"Hirsch","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s13238-021-00893-0","article-title":"Modeling hepatoblastoma development with human fetal liver organoids reveals YAP1 activation is sufficient for tumorigenesis","volume":"13","author":"Yang","year":"2022","journal-title":"Protein Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/hep.31389","article-title":"YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells","volume":"73","author":"Smith","year":"2021","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/CBM-200052","article-title":"USP7 promotes hepatoblastoma progression through activation of the PI3K\/AKT signaling pathway","volume":"31","author":"Ye","year":"2021","journal-title":"Cancer Biomark."},{"key":"ref_39","first-page":"566","article-title":"Clinical and Pathological Spectrum of Hepatoblastoma with Emphasis on Treatment-Induced Changes: Experience from Tertiary Care Center","volume":"46","author":"Ail","year":"2025","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0040-1722645","article-title":"Molecular mechanisms of hepatoblastoma","volume":"41","author":"Zhang","year":"2021","journal-title":"Semin. Liver Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s42003-021-02562-8","article-title":"Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma","volume":"4","author":"Bondoc","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12943-025-02405-8","article-title":"From preneoplastic lesion to heterogenous tumor: Recent insights into hepatoblastoma biology and therapeutic opportunities","volume":"24","author":"Yang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/sj.bjc.6604335","article-title":"Perinatal risk factors for hepatoblastoma","volume":"98","author":"Spector","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Voskamp, S., Nelson, J., and Speck, K.E. (2025). Hepatoblastoma: An investigation of diagnostic, prognostic, and therapeutic gene targets and biomarkers. Pediatr. Res., in press.","DOI":"10.1038\/s41390-025-04492-1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2407671","DOI":"10.1002\/advs.202407671","article-title":"Malignant hepatoblast-like cells sustain stemness via IGF2-dependent cholesterol accumulation in hepatoblastoma","volume":"12","author":"Ding","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kong, M., Zhai, Y., Liu, H., Zhang, S., Chen, S., Li, W., Ma, X., and Ji, Y. (2025). Insights into the mechanisms of angiogenesis in hepatoblastoma. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1535339"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/15513815.2021.2020384","article-title":"Yap expression is closely related to tumor angiogenesis and poor prognosis in hepatoblastoma","volume":"41","author":"Gong","year":"2022","journal-title":"Fetal Pediatr. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Prochownik, E.V., Henchy, C.M., and Wang, H. (2025). Hepatoblastoma cell lines: Past, present and future. Cells, 14.","DOI":"10.20944\/preprints202511.0664.v1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1573394716666200206103826","article-title":"Hepatoblastoma: Review of pathology, diagnosis and modern treatment strategies","volume":"16","author":"Abbas","year":"2020","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.18632\/oncotarget.26668","article-title":"mTOR inhibition affects Yap1-\u03b2-catenin-induced hepatoblastoma growth and development","volume":"10","author":"Molina","year":"2019","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"152478","DOI":"10.1016\/j.bbrc.2025.152478","article-title":"Efficient derivation of immortalized, isogenic cell lines from genetically defined murine hepatoblastomas","volume":"780","author":"Wang","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12943-016-0572-9","article-title":"The evolving concept of liver cancer stem cells","volume":"16","author":"Nio","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tranon.2018.10.008","article-title":"Targeting PIM kinases affects maintenance of CD133 tumor cell population in hepatoblastoma","volume":"12","author":"Stafman","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1038\/s41598-021-85289-0","article-title":"PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma","volume":"11","author":"Marayati","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e22620","DOI":"10.4161\/onci.22620","article-title":"Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma","volume":"2","author":"Hoh","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chen, K., Toksoz, A., Henchy, C., Knapp, J., Lu, J., Ranganathan, S., Wang, H., and Prochownik, E.V. (2025). Derivation of genetically defined murine hepatoblastoma cell lines with angiogenic potential. Cancers, 17.","DOI":"10.1101\/2025.07.25.666764"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1038\/s41467-022-32473-z","article-title":"Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids","volume":"13","author":"Song","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e70482","DOI":"10.1111\/jcmm.70482","article-title":"Intratumoral heterogeneity and immune microenvironment in hepatoblastoma revealed by single-cell RNA sequencing","volume":"29","author":"Ma","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e7154","DOI":"10.1002\/cam4.7154","article-title":"Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center","volume":"13","author":"Gikandi","year":"2024","journal-title":"Cancer Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00247-018-4078-z","article-title":"2017 PRETEXT: Radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT)","volume":"48","author":"Towbin","year":"2018","journal-title":"Pediatr. Radiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e28350","DOI":"10.1002\/pbc.28350","article-title":"The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children\u2019s Hepatic tumors International Collaboration (CHIC) database","volume":"67","author":"Haeberle","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"786","DOI":"10.2214\/AJR.20.25310","article-title":"Imaging for staging of pediatric abdominal tumors: An update, from the AJR Special Series on Cancer Staging","volume":"217","author":"Morin","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2022.06.013","article-title":"A novel risk stratification model based on the Children\u2019s Hepatic Tumours International Collaboration-Hepatoblastoma Stratification and deoxyribonucleic acid methylation analysis for hepatoblastoma","volume":"172","author":"Kondo","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): A prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e30302","DOI":"10.1002\/pbc.30302","article-title":"Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach","volume":"70","author":"Srinivasan","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00383-022-05356-z","article-title":"Surgical management in hepatoblastoma: Points to take","volume":"39","author":"Murawski","year":"2023","journal-title":"Pediatr. Surg. Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12262-023-03839-4","article-title":"Liver transplantation in children with advanced hepatoblastoma: A systematic review and meta-analysis","volume":"86","author":"Lai","year":"2024","journal-title":"Indian J. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1002\/cam4.5300","article-title":"Recent advances in surgical strategies and liver transplantation for hepatoblastoma","volume":"12","author":"Honda","year":"2023","journal-title":"Cancer Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/jhbp.1091","article-title":"The Tokyo 2020 terminology of liver anatomy and resections: Updates of the Brisbane 2000 system","volume":"29","author":"Wakabayashi","year":"2022","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1097\/JS9.0000000000002567","article-title":"Robotic versus laparoscopic liver resection: A systematic review and meta-analysis of comparative studies","volume":"111","author":"Hoogteijling","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/SLA.0000000000006505","article-title":"Ex-vivo liver resection and autotransplantation for liver malignancy: A large volume retrospective clinical study","volume":"280","author":"Aini","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00423-021-02310-w","article-title":"Vascular surgery in liver resection","volume":"406","author":"Weitz","year":"2021","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Moosburner, S., Schmelzle, M., Sch\u00f6ning, W., K\u00e4stner, A., Seika, P., Globke, B., Dziodzio, T., Pratschke, J., \u00d6llinger, R., and G\u00fcl-Klein, S. (2021). Liver transplantation is highly effective in children with irresectable hepatoblastoma. Medicina, 57.","DOI":"10.21203\/rs.3.rs-473238\/v1"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Leiskau, C., Junge, N., Mutschler, F.E., Laue, T., Ohlendorf, J., Richter, N., Vondran, F.W.R., Pfister, E.-D., and Baumann, U. (2023). Long-term outcome following liver transplantation for primary hepatic tumors\u2014A single centre observational study over 40 years. Children, 10.","DOI":"10.3390\/children10020202"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ramos-Gonzalez, G., LaQuaglia, M., O\u2019Neill, A.F., Elisofon, S., Zurakowski, D., Kim, H.B., and Vakili, K. (2018). Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. Pediatr. Transplant., e13250.","DOI":"10.1111\/petr.13250"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/LVT.0000000000000470","article-title":"Liver transplantation for pediatric liver malignancies","volume":"31","author":"Sakamoto","year":"2025","journal-title":"Liver Transplant."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MOP.0000000000000042","article-title":"Hepatoblastoma state of the art: Pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation","volume":"26","author":"Meyers","year":"2014","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ejca.2012.10.003","article-title":"Relapses in hepatoblastoma patients: Clinical characteristics and outcome\u2014Experience of the International Childhood Liver Tumour Strategy Group (SIOPEL)","volume":"49","author":"Semeraro","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Maxwell, R., H\u00e4berle, B., Kappler, R., von Schweinitz, D., Rassner, M., von Frowein, J., and Schmid, I. (2024). Hepatoblastoma relapse\u2014Findings from the German HB99 Trial and the German Liver Tumor Registry. Cancers, 16.","DOI":"10.3390\/cancers16040696"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e30576","DOI":"10.1002\/pbc.30576","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Liver tumors","volume":"70","author":"Meyers","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.dld.2025.06.017","article-title":"Identification of high-risk hepatoblastoma in the CHIC risk stratification system based on enhanced CT radiomics features","volume":"57","author":"Yang","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e6795","DOI":"10.1002\/cam4.6795","article-title":"Current trends and prospects of surgical techniques for hepatoblastoma","volume":"13","author":"Pu","year":"2024","journal-title":"Cancer Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"100235","DOI":"10.1016\/j.ejcped.2025.100235","article-title":"Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm\u2014Not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure","volume":"5","author":"Schmid","year":"2025","journal-title":"EJC Paediatr. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"73433","DOI":"10.18632\/oncotarget.20622","article-title":"Central role of mTORC1 downstream of YAP\/TAZ in hepatoblastoma development","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_87","unstructured":"(2026, February 16). Paediatric Hepatic International Tumour Trial (PHITT). ClinicalTrials.gov Identifier: NCT03017326, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(18)30895-7","article-title":"Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): A Children\u2019s Oncology Group, multicentre, phase 3 trial","volume":"20","author":"Katzenstein","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_89","unstructured":"(2026, February 16). Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Hepatoblastoma. ClinicalTrials.gov Identifier: NCT00980460, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_90","unstructured":"(2026, February 16). Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery (AHEP1531; HB-MRP Evaluation). ClinicalTrials.gov Identifier: NCT03533582, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.30591","article-title":"Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: A report from the Children\u2019s Oncology Group AHEP0731 study committee","volume":"123","author":"Katzenstein","year":"2017","journal-title":"Cancer"},{"key":"ref_92","unstructured":"(2026, February 16). Pucotenlimab Combined with Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed\/Refractory Hepatoblastoma in Children. ClinicalTrials.gov Identifier: NCT07188311, Available online: https:\/\/clinicaltrials.gov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.ejca.2011.12.032","article-title":"Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients","volume":"48","author":"Wagner","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajmg.a.38077","article-title":"Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome","volume":"173","author":"Mussa","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_95","first-page":"1739","article-title":"Prognostic implication of serum alpha-fetoprotein response to neoadjuvant chemotherapy in hepatoblastoma patients","volume":"6","author":"Attia","year":"2022","journal-title":"Int. J. Health Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease: Latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MOP.0000000000001088","article-title":"Liquid biopsies in pediatric oncology: Opportunities and obstacles","volume":"34","author":"Sundby","year":"2022","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e28594","DOI":"10.1002\/pbc.28594","article-title":"Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma","volume":"67","author":"McCowage","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kahana-Edwin, S., Torpy, J., Cain, L.E., Mullins, A., McCowage, G., Woodfield, S.E., Vasudevan, S.A., Shea, D.P.T., Minoche, A.E., and Espinoza, A.F. (2023). Quantitative ctDNA detection in hepatoblastoma: Implications for precision medicine. Cancers, 16.","DOI":"10.3390\/cancers16010012"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"100556","DOI":"10.1016\/j.jgeb.2025.100556","article-title":"Exploring the therapeutic potential of microRNAs: Targeted gene regulation strategies for enhanced cancer therapy","volume":"23","author":"Pandey","year":"2025","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Crist\u00f3bal, I., Sanz-\u00c1lvarez, M., Luque, M., Caram\u00e9s, C., Rojo, F., and Garc\u00eda-Foncillas, J. (2019). The role of microRNAs in hepatoblastoma tumors. Cancers, 11.","DOI":"10.3390\/cancers11030409"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"pbaf034","DOI":"10.1093\/pcmedi\/pbaf034","article-title":"Insights into the mechanisms of microRNAs in hepatoblastoma: From diagnosis to treatment","volume":"8","author":"Kong","year":"2025","journal-title":"Precis. Clin. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.2147\/IJGM.S331178","article-title":"Integrative analysis of DNA methylation and gene expression profiling data reveals candidate methylation-regulated genes in hepatoblastoma","volume":"14","author":"Wang","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: Advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Weigl, E.J., Demir, S., Schmid, T., Hotes, A., Muensterer, O., and Kappler, R. (2023). Establishing a three-dimensional scaffold model of hepatoblastoma. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1229490"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"42","DOI":"10.21037\/tgh.2019.12.03","article-title":"Hepatoblastoma: Current knowledge and promises from preclinical studies","volume":"5","author":"Calvisi","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"102647","DOI":"10.1016\/j.clinre.2025.102647","article-title":"Hepatic organoids as a platform for liver disease modeling and the development of novel therapies","volume":"49","author":"Luce","year":"2025","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2016.04.009","article-title":"Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer","volume":"65","author":"Legras","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/hep.31919","article-title":"Olaparib inhibits tumor growth of hepatoblastoma in patient-derived xenograft models","volume":"74","author":"Johnston","year":"2021","journal-title":"Hepatology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41390-024-03020-x","article-title":"Modelling the impact of liver regeneration on hepatoblastoma patient-derived xenograft tumor growth","volume":"96","author":"Cornet","year":"2024","journal-title":"Pediatr. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12935-022-02454-9","article-title":"Patient-derived xenograft models in hepatopancreatobiliary cancer","volume":"22","author":"Pan","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s12276-025-01487-0","article-title":"Perturbomics: CRISPR-Cas screening-based functional genomics approach for drug target discovery","volume":"57","author":"Park","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.7150\/ijbs.33481","article-title":"CRISPR\/Cas9-related technologies in liver diseases: From feasibility to future diversity","volume":"16","author":"Xu","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Zhu, Z., Shen, J., Ho, P.C., Hu, Y., Ma, Z., and Wang, L. (2025). Transforming cancer treatment: Integrating patient-derived organoids and CRISPR screening for precision medicine. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1563198"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"102611","DOI":"10.1016\/j.jceh.2025.102611","article-title":"The integration of multi-omics with artificial intelligence in hepatology: A comprehensive review of personalized medicine, biomarker identification, and drug discovery","volume":"15","author":"Ramesh","year":"2025","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"108785","DOI":"10.1016\/j.biotechadv.2025.108785","article-title":"Integrating multi-omics and artificial intelligence fuels advanced target identification and drug discovery","volume":"87","author":"Chen","year":"2025","journal-title":"Biotechnol. Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.acr.2024.06.005","article-title":"Multi-omics based artificial intelligence for cancer research","volume":"163","author":"Li","year":"2024","journal-title":"Adv. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s12672-025-02773-z","article-title":"Modern therapeutic approaches for hepatic tumors: Progress, limitations, and future directions","volume":"16","author":"Sadrinasab","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1038\/s41467-024-47280-x","article-title":"Single-cell multiomics reveals the interplay of clonal evolution and cellular plasticity in hepatoblastoma","volume":"15","author":"Roehrig","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2015.09.023","article-title":"The Children\u2019s Hepatic Tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model","volume":"52","author":"Czauderna","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/hep.32775","article-title":"Single-cell transcriptomics uncovers cellular architecture and developmental trajectories in hepatoblastoma","volume":"77","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4103\/0971-9261.142001","article-title":"The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials","volume":"19","author":"Aronson","year":"2014","journal-title":"J. Indian Assoc. Pediatr. Surg."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gizaw, A.T., Woldie, I., Yilma, A.N., Tadesse, M., Sisay, A.L., Sebero, F.M., Azalework, H.G., Dana, D., Sopory, P., and Hordofa, D.F. (2025). Barriers to timely diagnosis and treatment of childhood cancer in Sub-Saharan Africa: A qualitative systematic review. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15092-x"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e1195","DOI":"10.1016\/S2214-109X(21)00320-X","article-title":"Childhood cancer medicines: Understanding barriers to access","volume":"9","author":"Yadav","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Karim, A., Shaikhyzada, K., Suleimenova, A., Ibraimov, B., Nurgaliev, D., and Poddighe, D. (2022). Case report: Atypical teratoid\/rhabdoid tumor of the lateral ventricle in a male adolescent (case-based review and diagnostic challenges in developing countries). Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.985862"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"113583","DOI":"10.1016\/j.ejca.2024.113583","article-title":"Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival","volume":"200","author":"Pire","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"43","DOI":"10.15264\/cpho.2020.27.1.43","article-title":"Management of hepatoblastoma in the modern era and future perspectives","volume":"27","author":"Suh","year":"2020","journal-title":"Clin. Pediatr. Hematol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41575-020-0314-8","article-title":"Modern therapeutic approaches for the treatment of malignant liver tumours","volume":"17","author":"Petrowsky","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41598-025-31141-8","article-title":"Dinaciclib improves treatment response in chemoresistant hepatoblastoma","volume":"16","author":"Hickner","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Ferrero, J.M., Bouriga, R., Gal, J., and Milano, G. (2025). De-escalating anticancer treatment: Watch your step. Cancers, 17.","DOI":"10.3390\/cancers17152474"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/879\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:04:21Z","timestamp":1773072261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/5\/879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":130,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18050879"],"URL":"https:\/\/doi.org\/10.3390\/cancers18050879","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}